Humanin Peptide: The Mitochondria-Derived Longevity Signal

At a Glance

In my clinical work with patients navigating chronic illness, complex metabolism, and accelerated aging, I encounter a recurring pattern: the mitochondria are almost always implicated. We discuss ATP production, reactive oxygen species, and the well-known supplement strategies — CoQ10, NAD precursors, PQQ. What fewer practitioners discuss is that mitochondria are not passive energy factories. They are active endocrine organs, secreting signaling molecules that coordinate survival responses throughout the body.

Humanin is the founding member of this class. Discovered in 2001 by Hashimoto and colleagues while screening for factors that rescue neurons from Alzheimer’s-associated cell death, humanin has since accumulated a body of evidence suggesting it is a master regulator of cellular resilience. Its decline with age may be one of the underappreciated contributors to neurodegeneration, metabolic disease, and reduced stress tolerance in older adults.

This article covers what humanin is, what the research shows about its physiological roles, how levels can be measured and influenced, and where it fits in an evidence-informed longevity protocol.

What Is Humanin and Where Does It Come From?

Humanin (HN) is a 21-amino-acid peptide encoded within the 16S ribosomal RNA region of mitochondrial DNA — making it one of a small family of open-reading-frame peptides transcribed from the mitochondrial genome rather than the nuclear genome. This is unusual; most proteins are nuclear-encoded. The fact that mitochondria retain this signaling capacity suggests deep evolutionary conservation.

The mature peptide is secreted from cells and circulates in plasma, acting in both autocrine (same cell) and endocrine (distant tissue) fashions. Its primary membrane receptors include the gp130/CNTFR complex — shared with CNTF, a well-characterized neurotrophic factor — and FPR2/FPRL1, a G-protein–coupled receptor also activated by anti-inflammatory lipoxins. These receptor targets immediately hint at humanin’s dual roles in neural protection and immune modulation.

The MDP Family Context

Humanin belongs to a growing family of mitochondria-derived peptides (MDPs) that also includes MOTS-C (which I have covered separately) and the six small humanin-like peptides (SHLP1–6). Each has distinct tissue distribution and functional emphasis:

• MOTS-C: metabolic regulation, AMPK activation, exercise mimicry
• SHLP2 and SHLP3 — mitochondrial function, cancer cell apoptosis
• Humanin: neuroprotection, insulin signaling, cardiovascular protection

Together, these peptides represent a previously unrecognized mitochondrial language by which our cells communicate stress and resilience signals. Age-related decline in their levels may be as important as the better-known hormonal declines in understanding why aging tissues lose function.

Humanin Levels Decline Predictably With Age

Human and mouse studies that measured circulating humanin agree that levels decline with age (Muzumdar 2009, PMID: 19623253; Lee 2014, PMID: 25040290). In a 2020 study by Yen and colleagues (PMID: 32575074), circulating humanin in the children of centenarians was much higher than in age-matched controls, suggesting that humanin preservation may be a feature of successful aging rather than a passive bystander. The same group had earlier shown that SHLP2, a related mitochondrial peptide, also falls with age (Cobb 2016, PMID: 27070352).

Conditions associated with lower humanin levels include:

• Type 2 diabetes and insulin resistance
• Alzheimer’s disease and mild cognitive impairment
• Atherosclerosis and coronary artery disease
• Frailty and sarcopenia
• Chronic inflammatory states (elevated IL-6, TNF-α)

In my practice, when patients present with this cluster — metabolic dysfunction, cognitive complaints, cardiovascular risk, and chronic inflammation — I think of mitochondrial signaling capacity as a unifying thread.

Neuroprotective Mechanisms: The Original Discovery

The original 2001 paper by Hashimoto et al. (PMID: 11371646) identified humanin as a peptide that could rescue neuronal cell lines from death induced by multiple familial Alzheimer’s disease–associated genes (APP, presenilin-1, presenilin-2) and by amyloid-β itself. This finding was striking because no single factor had previously been shown to confer broad protection against such diverse neurotoxic insults.

Since then, humanin’s neuroprotective mechanisms have been characterized in considerable detail:

1. Inhibition of Bax-mediated mitochondrial apoptosis. Humanin binds directly to Bax, a pro-apoptotic BCL-2 family protein, preventing its translocation to the mitochondrial membrane and suppressing the cytochrome-c release cascade. This is a cell-autonomous survival mechanism.

2. Suppression of neuroinflammation. Via the FPR2 receptor and downstream NF-κB modulation, humanin reduces microglial activation and pro-inflammatory cytokine output. Given the central role of neuroinflammation in Alzheimer’s, Parkinson’s, and post-infectious brain fog, this pathway is clinically relevant.

3. STAT3-mediated trophic support. Signaling through gp130 activates STAT3, a transcription factor that upregulates neurotrophic genes including BDNF. This connects humanin to synaptic plasticity and neurogenesis.

4. Reduction of amyloid-β oligomer toxicity. Humanin can directly interact with Aβ aggregates, reducing their ability to form toxic oligomers. This raises the possibility that humanin decline contributes to amyloid pathology accumulation.

For patients presenting with post-COVID brain fog, Lyme-associated neurocognitive symptoms, or early cognitive decline, I consider the mitochondrial signaling axis — including humanin — as part of the biological picture alongside conventional workup.

Metabolic Effects: Insulin Sensitization and Glucose Homeostasis

A 2009 study by Muzumdar and colleagues (PMID: 19623253) demonstrated that humanin infused into the brain improves whole-body insulin sensitivity in rodents, an effect that depended on hypothalamic STAT3 signaling; intravenous infusion of potent humanin analogues reproduced it, and a single dose of a potent analogue lowered blood glucose in Zucker diabetic fatty rats.

In humans, cross-sectional analyses find that circulating humanin correlates inversely with fasting insulin, HOMA-IR (insulin resistance index), and visceral adiposity. Patients with type 2 diabetes have consistently lower humanin levels than matched controls.

The proposed mechanisms include:

• Central sensitization of hypothalamic insulin circuits
• Suppression of hepatic glucose output via STAT3 in hepatocytes
• Anti-inflammatory effects that reduce cytokine-driven insulin resistance
• Mitochondrial protection in pancreatic beta cells, preserving insulin secretory capacity

This metabolic profile places humanin alongside MOTS-C and other MDPs as part of the reason exercise and caloric restriction improve insulin sensitivity beyond their known mechanical effects — both interventions upregulate MDP expression.

Cardiovascular Protection

Cardiomyocytes are among the most mitochondria-dense cells in the body, and humanin exerts direct protective effects on heart tissue. In ApoE-knockout mice, humanin has been reported to slow atherosclerotic plaque progression by reducing foam cell formation and suppressing vascular inflammation — animal data that have not been tested in humans.

Key cardiovascular mechanisms:

• Anti-apoptotic effect in ischemia-reperfusion injury: Humanin pre-treatment reduces cardiomyocyte death when blood flow is experimentally restored after occlusion — the “reperfusion injury” paradigm relevant to post-MI tissue loss
• Endothelial protection: Humanin suppresses oxidized-LDL–induced endothelial cell death and adhesion molecule expression
• Platelet-activating factor antagonism: Via FPR2 receptor signaling, humanin partially antagonizes platelet-activating factor, a pro-thrombotic and pro-inflammatory mediator

The centenarian-offspring study cited above (Yen 2020) also found lower humanin in Alzheimer’s disease and MELAS; it did not report lipid, CRP or cardiovascular outcomes, so the cardiovascular case still rests on animal data.

How to Support Humanin Levels: Lifestyle and Therapeutic Strategies

No pharmaceutical humanin preparation is currently approved or available through regulated compounding in most jurisdictions. However, several strategies are supported by evidence to influence humanin expression or replicate aspects of its signaling:

Lifestyle Approaches

Supplement Stack Supporting MDP Signaling

• NAD+ precursors (NMN, NR): Sirtuins regulate mitochondrial biogenesis and MDP expression; NAD+ repletion supports this axis
• CoQ10/Ubiquinol: Maintains electron transport chain function, reducing mitochondrial stress that depletes MDPs
• Alpha-ketoglutarate: Supports mitochondrial TCA cycle function and has shown longevity effects in animal models
• Spermidine: Induces mitophagy, clearing dysfunctional mitochondria and stimulating biogenesis
• SS-31 (elamipretide): A mitochondria-targeted tetrapeptide that works at the structural level — binding cardiolipin on the inner mitochondrial membrane to restore cristae architecture and reduce electron leak. Where humanin acts through receptor signalling, SS-31 repairs the membrane platform that respiratory supercomplexes depend on — the two approaches are complementary.

Investigational Approaches

Synthetic humanin analogues — particularly HNG (humanin with glycine substitution at position 14) — show 1,000-fold greater potency than native humanin in preclinical models. HNG is used in research protocols but is not yet available clinically. ClinicalTrials.gov lists no interventional trial of humanin or HNG; the registered human studies only measure humanin as a biomarker.

Practitioners working with exosome therapies should also note that mesenchymal stem cell–derived exosomes contain MDPs including humanin, which may partly explain their observed neuroprotective and metabolic effects in some clinical series.

Dosing

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

No human dosing trial of humanin or its analogue HNG has been published, so every dose in circulation is either an animal dose or a community convention. The best-documented animal regimen is HNG at 4 mg/kg twice weekly by intraperitoneal injection for 14 months in middle-aged mice, which improved metabolic healthspan measures [6]. Community and reference sources describe 1-5 mg per subcutaneous injection two to three times weekly, in cycles of 4 to 12 weeks, and often cannot say whether the vial holds native humanin or HNG. The full protocol table, including where the sources disagree, is in the humanin dosage guide.

What people report: what works and what doesn’t

Sources: the aggregated community data (Peptide Protocol Wiki, 25 reports; Peptide DB), and a PepAtlas forum thread from people tracking labs on humanin (not linked, because the site’s security certificate has expired). The anecdotal record for humanin is thin, far thinner than for MOTS-c or SS-31, and many users take it together with MOTS-c, which makes attribution harder still. Patterns, not proof.

Reported to work

• A general sense of better recovery from training or physical stress, usually described as subtle and emerging after about two weeks at 1-5 mg two to three times weekly.
• Steadier day-to-day energy in a few reports, typically after two to four weeks.

Mixed or unclear

• Whether anything is happening at all. Most users describe effects as too subtle to attribute to humanin, and the aggregators frame it as a long-term anti-ageing bet rather than something you feel.
• Which molecule was injected. Most users believe they are taking HNG, but vendor labelling is inconsistent, so a report about “humanin” may be about either peptide at very different potency.
• Metabolic markers. A few forum users track fasting glucose, insulin, HOMA-IR or IGF-1 before and after a cycle. The one result posted so far was stable fasting glucose over 8 weeks, which could equally reflect diet and exercise.

Reported not to work, or disappointing

• No noticeable effect after 8 weeks at 5 mg twice weekly, beyond what the rest of the user’s regimen was already doing. Users who wait for a subjective effect tend to be disappointed.
• Side effects: none consistently described in the community data. That reflects how few people report, not demonstrated safety. The theoretical concern about chronic anti-apoptotic signalling and cancer remains untested.

What a properly designed trial would need to show: a dose-finding study of HNG or native humanin in older adults with insulin resistance or mild cognitive impairment, with pharmacokinetics, insulin sensitivity by clamp, cognitive testing over 6 to 12 months, cancer-related safety monitoring and a placebo arm.

Measuring Humanin Clinically

Plasma humanin can be quantified via ELISA (enzyme-linked immunosorbent assay) at specialty reference laboratories, though it is not yet a standard panel in most health systems. Reference ranges are not fully established, but published cohort data suggest:

• Young adults (20–40 years): ~1.5–3.0 ng/mL plasma
• Middle age (40–60 years): ~1.0–2.0 ng/mL
• Older adults (60–80 years): ~0.8–1.5 ng/mL
• Centenarian offspring: modestly but significantly higher than age-matched controls

Humanin is most informative when read alongside MOTS-C and other mitochondrial function markers, such as cardiolipin antibodies, an organic acids panel (for mitochondrial metabolite profiling) and the lactate-to-pyruvate ratio, when building a comprehensive mitochondrial health picture for patients with complex chronic disease or accelerated aging presentation.

Clinical Perspective: Where Humanin Fits

Humanin is not a standalone therapy today, but it represents a paradigm shift in how we understand aging biology. The finding that our own mitochondria encode survival signals — and that these signals predictably decline with age — adds a new dimension to longevity medicine beyond hormones, lifestyle, and conventional supplements.

For my patients, the practical takeaway is this: protect your mitochondria and they protect you. The strategies that keep mitochondria healthy — adequate NAD+ substrate, exercise-induced hormesis, strategic caloric restriction, targeted supplementation, and reduced toxic burden — are the same strategies that support humanin and the broader MDP axis.

As the synthetic analogue pipeline matures, I expect humanin-based interventions to become a meaningful tool in neuroprotection protocols, particularly for patients with early cognitive changes or high Alzheimer’s risk. I am watching the investigational HNG literature closely and will update this guidance when clinical-grade preparations become available.

Related Articles

• MOTS-C Peptide: Metabolic Regulation and Exercise Mimicry
• NAD+ Supplement Guide: NMN, NR, and IV Options Compared
• Mitochondrial Health: Why Your Power Plants Determine Your Longevity
• Peptide Therapy for Women: Hormones, Healing, and Longevity
• Longevity Supplement Stack: A Physician’s Evidence-Based Protocol